Our data indicate that serum KL-6 levels are markedly increased in IPF as compared to healthy subjects but we did not find reduced KL-6 levels in the patients treated by pirfenidone or nintedanib [20]. This evidence concerns the gene MUC1 and idiopathic pulmonary fibrosis.